Neurotech International Limited
Neurotech International Limited (NTI.AX) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Neurotech International Limited (NTI.AX), covering cash flow, earnings, and balance sheets.
Neurotech International Limited (NTI.AX) Income Statement & Financial Overview
Analyze Neurotech International Limited’s NTI.AX earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | -$33245.00 | $1507.00 | $2971.00 | $2988.00 |
| Cost of Revenue | $2.23M | $950703.00 | $2.21M | $2.02M |
| Gross Profit | -$2.27M | -$949196.00 | -$2.21M | -$2.02M |
| Gross Profit Ratio | $68.13 | -$629.86 | -$743.12 | -$675.27 |
| R&D Expenses | $3.01M | $2.24M | $4.25M | $2.21M |
| SG&A Expenses | $1.81M | $745468.00 | $50918.00 | $502301.00 |
| Operating Expenses | $4.82M | $2.98M | $4.30M | $2.71M |
| Total Costs & Expenses | $7.06M | $3.93M | $4.30M | $4.73M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $290.00 | $293.00 | $1156.00 | $588.00 |
| EBITDA | -$4.50M | -$3.90M | -$4.31M | -$4.73M |
| EBITDA Ratio | $135.31 | -$2608.83 | -$1445.07 | -$1581.93 |
| Operating Income | -$7.09M | -$3.93M | -$4.29M | -$4.73M |
| Operating Income Ratio | $213.23 | -$2609.02 | -$1445.46 | -$1582.13 |
| Other Income/Expenses (Net) | $2.75M | $27659.00 | $40956.00 | $426.00 |
| Income Before Tax | -$4.34M | -$3.90M | -$4.25M | -$4.73M |
| Income Before Tax Ratio | $130.56 | -$2590.67 | -$1431.67 | -$1581.98 |
| Income Tax Expense | $0.00 | -$3.18M | $4.00 | -$1.19M |
| Net Income | -$4.34M | -$728771.00 | -$4.25M | -$3.54M |
| Net Income Ratio | $130.56 | -$483.59 | -$1431.67 | -$1184.22 |
| EPS | -$0.005 | -$0.001 | -$0.005 | -$0.005 |
| Diluted EPS | -$0.005 | -$0.001 | -$0.005 | -$0.005 |
| Weighted Avg Shares Outstanding | $947.29M | $876.82M | $859.13M | $736.57M |
| Weighted Avg Shares Outstanding (Diluted) | $947.10M | $876.82M | $859.13M | $736.57M |
Over the last four quarters, Neurotech International Limited's revenue moved from $2988.00 in Q2 2023 to -$33245.00 in Q4 2024. Operating income in Q4 2024 was -$7.09M, with a strong operating margin of 21323%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Neurotech International Limited remained robust at -$4.50M, reflecting operational efficiency. Net income dropped to -$4.34M, with an EPS of -$0.005. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan